Overview

This trial is active, not recruiting.

Condition breast cancer
Treatment erlotinib with neoadjuvant chemotherapy
Phase phase 2
Sponsor University of Kansas
Collaborator Genentech, Inc.
Start date July 2007
End date December 2014
Trial size 32 participants
Trial identifier NCT00491816, 10864

Summary

Primary Study Objective:

To assess the pathological complete response rate (pCR) with 4-6 cycles of neoadjuvant chemotherapy plus erlotinib in patients with triple negative breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
erlotinib with neoadjuvant chemotherapy Tarceva
150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy

Primary Outcomes

Measure
Pathological complete response rate (pCR)
time frame: After 18 weeks of neoadjuvant therapy

Secondary Outcomes

Measure
Estimation of change in ki-67 (proliferation) after 2 cycles of neoadjuvant carboplatin/docetaxel based chemotherapy
time frame: After 2 cycles (6 weeks) of therapy
Estimation of change in ki-67 after 2 cycles of carboplatin/docetaxel based neoadjuvant chemotherapy plus erlotinib
time frame: After 2 cycles (6 weeks) of therapy
Assessment of toxicity of the combination of carboplatin/docetaxel chemotherapy plus erlotinib
time frame: During neoadjuvant chemotherapy
Assessment of tolerability of 12 months of maintenance erlotinib treatment
time frame: 12 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Female patient ≥ 18 years of age - Histologically proven stage II or III adenocarcinoma of the breast - Patients must be candidates for neoadjuvant treatment (tumor size > 2 cm, T2, T3, T4 and/or clinical N1 or N2) - Estrogen Receptor negative, Progesterone Receptor negative and HER-2 negative disease (IHC 0 or 1+ and/or FISH negative) - Performance status of 2 or better - No prior chemotherapy or endocrine therapy - If female of childbearing potential, pregnancy test is negative and willing to use effective contraception while on treatment and for at least 3 months after the last dose of study drug - Adequate bone marrow function: neutrophils ≥ 1500/mm3, platelet count ≥ 100,000/mm3, and hemoglobin ≥ 11 g/dL - Adequate kidney function: serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance of ≥ 60 mL/min - Adequate hepatic function: transaminases < 2 x upper limit of normal and total bilirubin ≤ 1.5 mg/dL - Patients must have a serum albumin ≥ 3.0 g/dL - Patients must have a Prothrombin Time, Partial Thromboplastin Time within normal limits - Patients must be informed of the investigational nature of the study, and must sign an informed consent in accordance with the institutional rules - Pretreatment lab values must be performed within 14 days of patient registration, and other baseline studies within 30 days - Patients will have a baseline mammogram, bone scan, CT chest and abdomen Exclusion Criteria: - Patients with metastatic disease are excluded from study - The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complications - Pregnancy or lactation - Prior use of an Epidermal growth factor receptor inhibitor - Patients with a history of chronic pulmonary disease are excluded from study - Patients with inadequate laboratory values (as defined above) are excluded from study - Patients with NCI common toxicity criteria (CTC) grade 2 or greater peripheral neuropathy are excluded from study - Patients with active infection are excluded from study - Patients with concomitant or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are excluded from study - Patients with emotional limitations are excluded from study - Patients with inflammatory breast cancer will be excluded

Additional Information

Official title Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer
Principal investigator Priyanka Sharma, M.D.
Description Twenty percent of women with breast cancer have triple negative breast cancer. The standard treatment for triple negative breast cancer is typically a combination of chemotherapy, surgery, +/- radiation therapy. When treated with standard therapy women with triple negative breast cancer have a worse long term outcomes as compared to women who do not have triple negative breast cancer. Triple negative breast cancer cells usually have a surface marker called EGFR (epidermal growth factor receptor). Women whose breast cancer cells have the EGFR surface marker have worse long term outcomes as compared to women whose tumors do not have the EGFR marker. Erlotinib (Tarceva) targets EGFR and is currently used for treatment of other cancers like lung and pancreas. This study will assess a combination of chemotherapy with erlotinib in women with triple negative breast cancer. For breast cancer patients who receive chemotherapy first and then get surgery, long-term survival is longer for women who do not have any microscopic cancer at the time of surgery. The primary objective of this study is to assess whether a combination of chemotherapy and erlotinib will result in no evidence of microscopic disease (pCR) at the time of surgery in greater than 20% of enrolled subjects. After completing all chemotherapy, patients will also receive maintenance erlotinib for 12 months. This is given to study the tolerability of maintenance Erlotinib and also to evaluate if maintenance erlotinib will decrease the rate of tumor recurrence.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by University of Kansas.